دورية أكاديمية
Prevalence and Distribution of Postvoid Residual Urine Volume in a Hospital-Based Sample of Men with Symptomatic Benign Prostatic Hyperplasia.
| العنوان: | Prevalence and Distribution of Postvoid Residual Urine Volume in a Hospital-Based Sample of Men with Symptomatic Benign Prostatic Hyperplasia. |
|---|---|
| المؤلفون: | Anyimba SK; Urology Unit, Department of Surgery, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria., Amu OC, Nnabugwu II, Okoh AD, Nwachukwu CD, Iwenofu CA |
| المصدر: | Nigerian journal of clinical practice [Niger J Clin Pract] 2023 Dec 01; Vol. 26 (12), pp. 1839-1843. Date of Electronic Publication: 2023 Dec 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medknow Publications Country of Publication: India NLM ID: 101150032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1119-3077 (Print) NLM ISO Abbreviation: Niger J Clin Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Mumbai : Medknow Publications Original Publication: [Lagos?] : Medical and Dental Consultants' Association of Nigeria |
| مواضيع طبية MeSH: | Prostatic Hyperplasia*/diagnosis , Prostatic Hyperplasia*/epidemiology , Prostatic Hyperplasia*/complications , Lower Urinary Tract Symptoms*/epidemiology , Lower Urinary Tract Symptoms*/diagnosis , Urinary Bladder Neck Obstruction* , Urinary Retention*, Male ; Humans ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Quality of Life ; Prevalence ; Prostate-Specific Antigen |
| مستخلص: | Background: Benign prostatic hyperplasia (BPH) is a known cause of bladder outlet obstruction (BOO) in aging men. Patients present with lower urinary tract symptoms (LUTS), elevated postvoid residual urine (PVR), and reduced peak flow rate of urine. Although urodynamic study is the gold standard for diagnosing and quantifying BOO, it is invasive and as such urologists in their routine practice frequently rely on less invasive methods like PVR estimation to objectively assess BOO. Aim: To study the prevalence and distribution of PVR in a hospital-based population of men with symptomatic BPH. Materials and Methods: Patients aged 40 years and above were enrolled for the study. History was taken from each of the 170 participants recruited, and physical examination was done including digital rectal examination. Every one of them completed the International Prostate Symptom Score (IPSS) questionnaire and also had ultrasonography assessment of PVR. Relevant laboratory investigations (PSA, renal function test, full blood count, urinalysis, and urine culture) and uroflowmetry to determine the peak flow rate of urine (Qmax) were done. Results: A total of 170 subjects who met the inclusion criteria were enrolled for this study. The mean age of the subjects was 63.70 ± 9.92 years with a range of 42-88 years. The subjects had a mean PSA of 2.68 ± 0.91 ng/ml and a mean prostate volume of 70.8 ± 39.5 ml. The prevalence of significant PVR was 57.06%. The distribution of PVR was skewed with values ranging from 4.0 ml to 382.9 ml, a median value of 60.5 ml (interquartile range, IQR, =25.0-100.76), and a mean value of 77.70 ± 69.30 ml. An IPSS range of 8 to 23 with a mean value of 13.64 ± 4.14 and a median value of 13 (interquartile range = 10.0-16.0) was observed. The Qmax range was from 5 ml/s to 50 ml/s with a mean value of 20.25 ± 9.70 ml/s, and a median value of 18.0 ml/s (interquartile range = 14.0-24.0). Conclusion: This study showed that the prevalence of significant PVR volume among men with symptomatic BPH in our environment is high. There was also a high variation in the distribution of PVR among the subjects. Therefore, it is essential to create more public awareness especially among men in their fourth decade of life and above to visit a urologist whenever they have BPH symptoms so as to avoid impairment in quality of life and renal function associated with neglected significant PVR. (Copyright © 2023 Copyright: © 2023 Nigerian Journal of Clinical Practice.) |
| References: | Malik MA, Khan JH, Gondal WS, Bajwa IA. Role of uroflowmetry in lower urinary tract symptoms evaluation due to benign prostatic hyperplasia. Annals of king Edward Medical University. Annals of KEMU 2010;16:34–8. Güler C, Tüzel E, Doğantekin E, Kiziltepe G. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 2008;80:181–5. Mock S, Dmochowski R. Benign prostatic hyperplasia and related entitles. In: Hanno MP, Guzzo TJ, Malkowicz SB, Wein AJ, editors. Penn Clinical Manual of Urology. 2nd ed. Philadelphia: Elsevier Saunders; 2014. p. 474. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follows-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40. Adewumi OA, Sulyman AK, Benjamin AO. Sonographic assessment of postvoid residual urine volumes in patients with benign prostatic hyperplasia. J Natl med Assoc 2004;96:234–9. Ding yy, Sahadevan WP, Choo WJ. Clinical utility of a portable ultrasound scanner in the measurement of residual urine. Singapore Med J 1996;37:365–8. Simforoosh N, Dadkhah F, Hosseini SY, Asgari MA, Nasseri A, Safarinejad MR. Accuracy of residual urine measurement in men: Comparison between real time ultrasonography and catherization. J Urol 1997;158:59–61. Coombes GM, Millard RJ. The accuracy of portable ultrasound scanning in the measurement of residual urine volume. J Urol 1994;152:2083–5. Bent AE, Nahhas DE, McLennan MT. Portable ultrasound determination of urinary residual volume. Int Urogynecol J 1997;8:200–2. Beacock CJ, Roberts EE, Rees RW, Buck AC. Ultrasound assessment of residuals urine: A qualitative method. Br J Urol 1985;57:410–13. Fuse H, Yokoyama T, Muraishi Y, Katayama T. Measurements of residual urine volume using a portable ultrasound instrument. Int Urol Nephrol 1996;28:633–7. Gerst S, Hricak H. Radiology of the urinary tract. In: McAninch JW, Lue TF. editors. Smith and Tanagho’s General Urology. 18th ed. New York: Mc Graw Hill; 2013. p. 81. Amu OC, Udeh EI, Ugochukwu AI, Dakum NK, Ramyil VM. The value of International prostate symptom scoring system in the management of BPH in JOS, Nigeria. Niger J Clin Pract 2013;16:273–8. Ojewola RW, Oridota ES, Balogun OS, Alabi TO, Ajayi AI, Olajide TA, et al. Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a South-West Nigerian rural setting: A cross-sectional study. Afr J Urol 2017;23:109–15. Eze BU, Mbaeri TU, Orakwe JC. Anterior bladder wall thickness, post-void urine residue and bladder emptying efficiency as indicators of dysfunction in Nigerian men with benign prostatic hyperplasia. Niger J Clin Pract 2020;23:1215–20. Bhomi KK, Joshi BR. Correlation between symptom severity and objective parameters in elderly men with lower urinary tract symptoms. Nepal Med Coll J 2019;21;117–21. Hamza BK, Ahmed M, Bello A, Tolani MA, Awaisu M, Lawal AT, et al. Correlation of intravesical prostatic protrusion with severity of lower urinary symptoms among patients with benign prostatic hyperplasia. Afr J Urol 2021;27:1–7. Sigdel G, Belokar WK. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic hyperplasia. J Univ Coll Med Sci 2015;3:6–10. Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, et al. Prevalence of BPH and lower urinary tract symptoms in West Africans. Prostate cancer prostatic Dis 2012;15:170–6. Elsaied W, Mosharafa A, Elfayoumy H, ElGhoniemy M, Ziada A, ElGhamrawy H, et al. Detrusor wall thickness compared to other non-invasive methods in diagnosing men with bladder outlet obstruction: A prospective controlled study. Afr J Urol 2013;19:160–4. Chikkaraddi ML, Manjunath S. Uroflowmetry evaluation of lower urinary tract symptoms in patients with benign prostatic hyperplasia an institutional study. Int J Recent Trends Sci Technol 2014;12:454–7. Thapa N, Agrawal CS. Correlation of uroflowmetry with lower urinary tract symptoms in patients with symptomatic benign prostatic hyperplasia at eastern part of Nepal: A prospective study. IOSR JDMS 2017;16:86–91. Hamid SH, Mohamedahmed AY, Sharfi AR. Correlation between the size of the prostate, post void residual volume, PSA level and IPSS in Men with LUTS in three major Urology centres in Khartoum. Int J Surg Res 2020;9:1–8. doi: 10.5923/j.surgery. 20200901.01. Roehrborn CG. Alfuzocin 10mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2- year placebo-controlled study. BJU Int 2006;97:734–41. |
| المشرفين على المادة: | EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20231229 Date Completed: 20240103 Latest Revision: 20240103 |
| رمز التحديث: | 20240103 |
| DOI: | 10.4103/njcp.njcp_339_23 |
| PMID: | 38158350 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1119-3077 |
|---|---|
| DOI: | 10.4103/njcp.njcp_339_23 |